KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Current Assets (2016 - 2026)

Biogen has reported Current Assets over the past 18 years, most recently at $9.2 billion for Q1 2026.

  • For Q1 2026, Current Assets rose 20.51% year-over-year to $9.2 billion; the TTM value through Mar 2026 reached $9.2 billion, up 20.51%, while the annual FY2025 figure was $9.0 billion, 20.35% up from the prior year.
  • Current Assets for Q1 2026 was $9.2 billion at Biogen, up from $9.0 billion in the prior quarter.
  • Over five years, Current Assets peaked at $10.4 billion in Q2 2023 and troughed at $6.8 billion in Q1 2024.
  • A 5-year average of $8.4 billion and a median of $8.5 billion in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: surged 36.35% in 2022 and later crashed 31.86% in 2024.
  • Year by year, Current Assets stood at $9.8 billion in 2022, then decreased by 29.94% to $6.9 billion in 2023, then rose by 8.71% to $7.5 billion in 2024, then rose by 20.35% to $9.0 billion in 2025, then increased by 2.41% to $9.2 billion in 2026.
  • Business Quant data shows Current Assets for BIIB at $9.2 billion in Q1 2026, $9.0 billion in Q4 2025, and $8.9 billion in Q3 2025.